Memory B lymphocytes determine repertoire oligoclonality early after haematopoietic stem cell transplantation
Article first published online: 8 SEP 2003
DOI: 10.1046/j.1365-2249.2003.02260.x
Additional Information
How to Cite
OMAZIC, B., LUNDKVIST, I., MATTSSON, J., PERMERT, J. and NÄSMAN-BJÖRK, I. (2003), Memory B lymphocytes determine repertoire oligoclonality early after haematopoietic stem cell transplantation. Clinical & Experimental Immunology, 134: 159–166. doi: 10.1046/j.1365-2249.2003.02260.x
Publication History
- Issue published online: 8 SEP 2003
- Article first published online: 8 SEP 2003
- (Accepted for publication 22 July 2003)
- Abstract
- Article
- References
- Cited By
Keywords:
- B lymphocyte repertoire;
- haematopoietic stem cell transplantation;
- IgH gene expression;
- immune reconstitution
SUMMARY
The objective of this study was to investigate if oligoclonality of the Ig repertoire post-haematopoietic stem cell transplantation (HSCT) is restricted to memory B lymphocytes or if it is a general property among B lymphocytes. As a measure of B lymphocyte repertoire diversity, we have analysed size distribution of polymerase chain reaction (PCR) amplified Ig H complementarity determining region 3 (CDR3) in naive and memory B lymphocytes isolated from patients before HSCT and at 3, 6 and 12 months after HSCT as well as from healthy controls. We demonstrate a limited variation of the IgH CDR3 repertoire in the memory B lymphocyte population compared to the naive B cell population. This difference was significant at 3 and 6 months post-HSCT. Compared to healthy controls there is a significant restriction of the memory B lymphocyte repertoire at 3 months after HSCT, but not of the naive B lymphocyte repertoire. Twelve months after HSCT, the IgH CDR3 repertoire in both memory and naive B lymphocytes are as diverse as in healthy controls. Thus, our findings suggest a role for memory B cells in the restriction of the oligoclonal B cell repertoire observed early after HSCT, which may be of importance when considering reimmunization of transplanted patients.

1365-2249/asset/cei_left.gif?v=1&s=ffee144c532fe5e73bbb89290ba14e154b0d400b)
1365-2249/asset/cei_right.gif?v=1&s=c14d545a5215173707c8202758d5b25fd0bede44)
1365-2249/asset/cover.gif?v=1&s=d4467d7f3170476372896b9f36344ab40422bf6f)